Event Calendar

Share This

KL2 Visiting Scholar Seminar Series: Deliver Nanomedicines to Lymph Nodes and Tumor to Potentiate Melanoma Immunotherapy

Date Wed, Jun 17
Time 12: 00 PM - 1: 00 PM
Location Zoom Webinar

This seminar is part of the GHUCCTS KL2 Visiting Scholars Seminar Series.

Dr. Guizhi Julian Zhu is an Assistant Professor of Pharmaceutics, and Pharmaceutical Engineering and Sciences in Virginia Commonwealth University (VCU). He is also an NCATS KL2 Scholar, an associate member of VCU Massey Cancer Center, and a member of VCU Institute for Structural Biology, Drug Discovery and Development (ISB3D). He received PhD in Biomedical Sciences from the University of Florida, followed by a postdoc training on drug delivery and bioimaging in the National Institute of Biomedical Imaging and Bioengineering (NIBIB) of NIH. His multidisciplinary research group studies the delivery of immune drugs, often nucleic acid therapeutics, for the immunotherapy of cancer and autoimmune diseases. He has published over 80 peer-reviewed papers.

ABSTRACT: "The ultimate goal of my research group is to develop clinically translatable cancer therapeutics. In this talk, we will discuss a novel and simple drug delivery systems based on reversibly albumin- binding prodrugs for efficient delivery to tissues and cells in cancer immunotherapy, gene therapy, and chemotherapy. We will discuss the delivery of multiple types of drugs including small molecule immunostimulants, oligonucleotides, peptides, and chemotherapeutics, for the delivery to tumor tissues or cells as well as lymphoid tissues and antigen-presenting cells. Such albumin-binding technology enhanced the in vivo half-lives and tissue delivery efficiencies by up to 2 orders of magnitudes, while reducing off-target dissemination and toxicities. The efficient drug delivery potentiated the therapeutic efficacy for tumor, including a combination melanoma immunotherapy based on albumin-binding vaccines and immune checkpoint blockade. Worth noting, the reversible albumin binder is derived from Evans blue that has been used in the clinic for nearly a century, and the resulting Evans blue derivative was validated for tumr or lymph node targeting with undetectable toxicities in clinic trails, which should facilitate the clinical translation of this type of
drug delivery system."

Upcoming Events
Sep 23
TBS Workshop Scholar Presents Series: Final Scholar Presentations  Sep 23, 2021  5: 30 PM - 7: 30 PM  Virtual
TBS Workshop Scholar Presents Series: Final Scholar Presentations from Sean Carey, PhD Candidate; Sarra Djemil, PhD; Shiva Hassanzadeh-Behbahani, PhD Candidate; & Chaz Hinzman, PhD Candidate. Event is Virtual, September 23, 2021 from 5:30 PM to 7:30 PM.
Sep 30
TBS Workshop Scholars Present Series: Final Presentations  Sep 30, 2021  5: 30 PM - 7: 30 PM  Virtual
TBS Workshop Scholar Presents Series: Final Scholar Presentations from Martha Gay, PhD; Lauren Rosko, PhD Candidate; Bryce Jones, MD/PhD Candidate; & Paige Brooks, PhD Candidate. Event is Virtual, September 30, 2021 from 5:30 PM to 7:30 PM.
This month's MHRI-GHUCCTS Monthly Statistical Seminar Series will be held Friday, October 15, 2021 online from 12 PM to 1 PM. This series features Dr. Paul Kolm, Associate Director in the Department of Biostatistics and Biomedical Informatics at MedStar Health Research Institute. Dr. Kolm will present on the topic Analytic Complexities of Observational Data: A Study of Modeling Atrial Fibrillation
Oct 21
TBS Workshop Scholar Presents Series: Update Scholar Presentations  Oct 21, 2021  5: 30 PM - 7: 30 PM  Virtual
The TBS Workshop Scholar Presents Series: Update Scholar presentations from Alex Brunfeldt, PhD; Joseph Aubee, PhD Candidate; Plamen Nikolov, PhD Candidate; & Collis Brown, PhD Candidate